Celgene adds big OK for Otezla; Vitae takes a haircut on IPO price; ZS touts PhIII hyperkalemia data;

@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech

@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce

@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce

> Celgene ($CELG) added a big approval for Otezla, gaining the FDA's approval to market the drug for psoriasis. Story

> Vitae Pharmaceuticals ($VTAE) priced its IPO at $8 a share, well below its proposed range of $11 to $13 a share. Release

> Texas-based ZS Pharma ($ZSPH) says it garnered positive data for its second Phase III clinical trial of ZS-9 (sodium zirconium cyclosilicate), which has been in the clinic for hyperkalemia. Release

Medical Device News

@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2

@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce

> Little is known about the Sunshine Act site ahead of launch, AdvaMed says. Article

> FDA to weigh in on cybersecurity concerns. Report

Pharma News

@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce

> GlaxoSmithKline soon to name RBS chair Hampton as next chairman. Report

> Oh, what a tangled web of pharma M&A, starring Pfizer, Actavis, Allergan and Salix. Story

> Ackman threatens Allergan with lawsuit if Salix deal is sealed. Article

Drug Delivery News

> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item

> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report

> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story

> Titan Pharma trial of implant for addicts on track. Article

> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More

Diagnostics News

> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News

> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report

> Sequenom keeps prenatal Dx competition running with new positive data. Article

> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story

> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More

Pharma Marketing News

> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report

> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More

> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item

> Can copay coupons be kickbacks? HHS says yes. More

> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.